Lucid Diagnostics Inc. · NASDAQ:LUCD
Lucid Diagnostics — Q4 2024 Earnings Presentation
16 slides from Lucid Diagnostics's earnings presentation, Mar 24, 2025
Slide 1: Q4 2024 Business Update
Nasdaq: LUCD Q4 2024 Business Update March 24, 2025 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the “Company”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors th
Slide 3: Lishan Aklog, M.D. Chairman & CEO
Lishan Aklog, M.D. Chairman & CEO
Slide 4: Highlights: Commercial Execution
Highlights ▪ Commercial Execution – 4Q24 Revenue $1.2M – 4Q24 EsoGuard test volume 4,042: +45% Quarterly Record quarterly test volume – Restructured commercial team and compensation model to focus on revenue- driving activities – Executed over 20 concierge medicine contracts, expanding EsoGuard acce
Slide 5: Highlights: Key Strategic Accomplishments
Highlights ▪ Key Strategic Accomplishments – Highmark Blue Cross Blue Shield in New York established positive commercial insurance coverage policy for EsoGuard – National Comprehensive Cancer Network ® (NCCN) updates Clinical Practice Guidelines to include section on esophageal precancer screening a
Slide 6: Commercial-Stage Cancer Prevention Solution
COMMERCIAL- STAGE CANCER PREVENTION SOLUTION Comprehensive Precancer Screening Solution Our Mission is to Prevent Esophageal Cancer Deaths in At-risk Patients 6
Slide 7: EsoGuard Revenue & Test Volume
EsoGuard Revenue & Test Volume $1,400,000 4,500 Revenue Tests 4,000 $1,200,000 ~$60B Total Addressable U.S. Market 3,500 $1,000,000 3,000 $800,000 2,500 $600,000 ~30,000 Cumulative EsoGuard Tests 2,000 Performed Since Launch 1,500 $400,000 1,000 $200,000 500 $0 0 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1
Slide 8: Business Update
Dlucid wes By Business Update
Slide 9: Reimbursement Update
Reimbursement Update SHIGHMARK. National Comprehensive iNCeene Cancer Network® PALMETTO GBA ©. CEMsS CENTERS FOR MEDICARE & MEDICAID SERVICES MolDX [Lucid
Slide 10: Sales Channels
Traditional Primary Care & Specialists Revenue Cycle Management (RCM) Medicare and Commercial Payors Direct Contracting SALES Employers CHANNELS Self-Insured Entities Fire Departments Cash Pay Concierge Medicine 10
Slide 11: Q4 2024 Financial Update
Q4 2024 Financial Update Dennis McGrath, CFO
Slide 12: Balance Sheet
Balance Sheet ($ in thousands) 3Q24 4Q24 Change Assets Cash $14,489 $22,358 $7,869 Fixed Assets 940 1,062 122 All other Assets 7,169 7,295 126 Liabilities Accounts Payable 1,135 1,241 106 Senior Secured Convertible Notes 10,200 18,600 8,400 Other Current Liabilities 2,914 3,683 769 Long-Term Liabili
Slide 13: P&L
P&L ($ in thousands) 4Q23 4Q24 Change 4Q23 - YTD 4Q24 - YTD Change Revenue $1,040 $1,197 $157 $2,428 $4,346 $1,918 Operating Expenses $12,494 $13,571 $1,077 $50,910 $50,398 $(512) Net Loss $(10,829) $(11,541) $(712) $(52,666) $(45,529) $7,137 EBITDA $(10,285) $(11,377) $(1,092) $(50,175) $(44,658) $
Slide 14: Non-GAAP Operating Expense
Non-GAAP Operating Expense To supplement our audited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. Non-GAAP financial measures are presented with the int
Slide 15: Q&A
Q&A
Slide 16: Closing Remarks
Dlucid wes By Closing Remarks